David B Olawade, Aanuoluwapo Clement David-Olawade, Temitope Adereni, Eghosasere Egbon, Jennifer Teke, Stergios Boussios
{"title":"将人工智能与癌症免疫治疗相结合——当前应用和未来发展方向综述。","authors":"David B Olawade, Aanuoluwapo Clement David-Olawade, Temitope Adereni, Eghosasere Egbon, Jennifer Teke, Stergios Boussios","doi":"10.3390/diseases13010024","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cancer remains a leading cause of morbidity and mortality worldwide. Traditional treatments like chemotherapy and radiation often result in significant side effects and varied patient outcomes. Immunotherapy has emerged as a promising alternative, harnessing the immune system to target cancer cells. However, the complexity of immune responses and tumor heterogeneity challenges its effectiveness.</p><p><strong>Objective: </strong>This mini-narrative review explores the role of artificial intelligence [AI] in enhancing the efficacy of cancer immunotherapy, predicting patient responses, and discovering novel therapeutic targets.</p><p><strong>Methods: </strong>A comprehensive review of the literature was conducted, focusing on studies published between 2010 and 2024 that examined the application of AI in cancer immunotherapy. Databases such as PubMed, Google Scholar, and Web of Science were utilized, and articles were selected based on relevance to the topic.</p><p><strong>Results: </strong>AI has significantly contributed to identifying biomarkers that predict immunotherapy efficacy by analyzing genomic, transcriptomic, and proteomic data. It also optimizes combination therapies by predicting the most effective treatment protocols. AI-driven predictive models help assess patient response to immunotherapy, guiding clinical decision-making and minimizing side effects. Additionally, AI facilitates the discovery of novel therapeutic targets, such as neoantigens, enabling the development of personalized immunotherapies.</p><p><strong>Conclusions: </strong>AI holds immense potential in transforming cancer immunotherapy. However, challenges related to data privacy, algorithm transparency, and clinical integration must be addressed. Overcoming these hurdles will likely make AI a central component of future cancer immunotherapy, offering more personalized and effective treatments.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":"13 1","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764268/pdf/","citationCount":"0","resultStr":"{\"title\":\"Integrating AI into Cancer Immunotherapy-A Narrative Review of Current Applications and Future Directions.\",\"authors\":\"David B Olawade, Aanuoluwapo Clement David-Olawade, Temitope Adereni, Eghosasere Egbon, Jennifer Teke, Stergios Boussios\",\"doi\":\"10.3390/diseases13010024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cancer remains a leading cause of morbidity and mortality worldwide. Traditional treatments like chemotherapy and radiation often result in significant side effects and varied patient outcomes. Immunotherapy has emerged as a promising alternative, harnessing the immune system to target cancer cells. However, the complexity of immune responses and tumor heterogeneity challenges its effectiveness.</p><p><strong>Objective: </strong>This mini-narrative review explores the role of artificial intelligence [AI] in enhancing the efficacy of cancer immunotherapy, predicting patient responses, and discovering novel therapeutic targets.</p><p><strong>Methods: </strong>A comprehensive review of the literature was conducted, focusing on studies published between 2010 and 2024 that examined the application of AI in cancer immunotherapy. Databases such as PubMed, Google Scholar, and Web of Science were utilized, and articles were selected based on relevance to the topic.</p><p><strong>Results: </strong>AI has significantly contributed to identifying biomarkers that predict immunotherapy efficacy by analyzing genomic, transcriptomic, and proteomic data. It also optimizes combination therapies by predicting the most effective treatment protocols. AI-driven predictive models help assess patient response to immunotherapy, guiding clinical decision-making and minimizing side effects. Additionally, AI facilitates the discovery of novel therapeutic targets, such as neoantigens, enabling the development of personalized immunotherapies.</p><p><strong>Conclusions: </strong>AI holds immense potential in transforming cancer immunotherapy. However, challenges related to data privacy, algorithm transparency, and clinical integration must be addressed. Overcoming these hurdles will likely make AI a central component of future cancer immunotherapy, offering more personalized and effective treatments.</p>\",\"PeriodicalId\":72832,\"journal\":{\"name\":\"Diseases (Basel, Switzerland)\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764268/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diseases (Basel, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/diseases13010024\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/diseases13010024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:癌症仍然是世界范围内发病率和死亡率的主要原因。传统的治疗方法,如化疗和放疗,往往会导致严重的副作用和不同的患者结果。免疫疗法已经成为一种很有前途的替代疗法,利用免疫系统来靶向癌细胞。然而,免疫反应的复杂性和肿瘤的异质性挑战了其有效性。目的:本文探讨人工智能(AI)在提高癌症免疫治疗疗效、预测患者反应和发现新的治疗靶点方面的作用。方法:全面回顾文献,重点关注2010年至2024年间发表的关于人工智能在癌症免疫治疗中的应用的研究。利用PubMed、b谷歌Scholar和Web of Science等数据库,根据与主题的相关性选择文章。结果:人工智能通过分析基因组、转录组学和蛋白质组学数据,对识别预测免疫治疗疗效的生物标志物做出了重大贡献。它还通过预测最有效的治疗方案来优化联合疗法。人工智能驱动的预测模型有助于评估患者对免疫治疗的反应,指导临床决策并最大限度地减少副作用。此外,人工智能有助于发现新的治疗靶点,如新抗原,从而实现个性化免疫疗法的发展。结论:人工智能在改变癌症免疫治疗方面具有巨大的潜力。然而,与数据隐私、算法透明度和临床整合相关的挑战必须得到解决。克服这些障碍可能会使人工智能成为未来癌症免疫治疗的核心组成部分,提供更加个性化和有效的治疗。
Integrating AI into Cancer Immunotherapy-A Narrative Review of Current Applications and Future Directions.
Background: Cancer remains a leading cause of morbidity and mortality worldwide. Traditional treatments like chemotherapy and radiation often result in significant side effects and varied patient outcomes. Immunotherapy has emerged as a promising alternative, harnessing the immune system to target cancer cells. However, the complexity of immune responses and tumor heterogeneity challenges its effectiveness.
Objective: This mini-narrative review explores the role of artificial intelligence [AI] in enhancing the efficacy of cancer immunotherapy, predicting patient responses, and discovering novel therapeutic targets.
Methods: A comprehensive review of the literature was conducted, focusing on studies published between 2010 and 2024 that examined the application of AI in cancer immunotherapy. Databases such as PubMed, Google Scholar, and Web of Science were utilized, and articles were selected based on relevance to the topic.
Results: AI has significantly contributed to identifying biomarkers that predict immunotherapy efficacy by analyzing genomic, transcriptomic, and proteomic data. It also optimizes combination therapies by predicting the most effective treatment protocols. AI-driven predictive models help assess patient response to immunotherapy, guiding clinical decision-making and minimizing side effects. Additionally, AI facilitates the discovery of novel therapeutic targets, such as neoantigens, enabling the development of personalized immunotherapies.
Conclusions: AI holds immense potential in transforming cancer immunotherapy. However, challenges related to data privacy, algorithm transparency, and clinical integration must be addressed. Overcoming these hurdles will likely make AI a central component of future cancer immunotherapy, offering more personalized and effective treatments.